Vireo Growth $VREOF Read from its own SEC filings · nothing written, nothing inferred
🫧 Edgar looked up VIREO GROWTH INC. ($VREOF). Last filing: 8-K (2.01 Completion of Acquisition or Disposition of Assets), 2026-08-26. 29 event filings (8-K) in the past twelve months. Auditor change (8-K Item 4.01) filed 2026-06-09.
🔖 Exposure: revenue $268.8M (FY2025). Experience: revenue up 170.4% on the year, up 49.1% a year over 4 years; operating margin -0.4%, down from 13.6%. Soundness: equity 37.6% of assets, return on equity -22.2%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $346.0M and $912.3M next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; on a year the method never saw, 83.4% landed inside). In a shock year the stress range is $270.7M to $1.2B. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -0.4% against a -3.8% median; growth 170.4% against 13.7%.
Speed and cash · fiscal 2025
Both views must agree for a label · a description, not advice.
| Cash flow (op · inv · fin · free) | $4M · $9M · $18M · −$25M |
| Investment book (cash · short · long) | $122M · $1M · $6M · current ratio 1.59 |
| Revenue swing · equity of assets | 40.6% · 37.6% |
Vireo Growth is growing faster than its size class, with revenue that swings more. Its own audited SEC figures.
The figures, as filed
| Fiscal year end | 2025-12-31 |
| Revenue | $269M |
| Revenue, on the year | 170.4% |
| Revenue, a year over the record | 49.1% |
| Operating margin | −0.4% |
| Operating margin, prior year | 13.6% |
| Net margin | −25.3% |
| Research and development | not filed separately |
| Total debt | — |
| Equity of assets | 37.6% |
| Return on equity | −22.2% |
| Payout of profit | — |
| Dividend per share | — |
| Earnings per share | $-0.09 |
| Book value per share | $0.42 |
| Revenue per share | $0.37 |
| Shares outstanding | 734,738,785 |
| Audited years read | 5 |
Peers: the median of 114 filers with $50M+ revenue in pharmaceutical preparations.
Health HarborVireo Growth sails as: Weathered boat
Health watch · 12 monthsAuditor changeDirector or officer change
Sailing speed follows growth: 53.3% a year crosses the harbor in 30 seconds.
🌊 Visit the Bay →- filed auditor change in the last 12 months
- revenue is hard to predict: its 80% range is ±45%
Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider. A picture of the signs, not a rating and not investment advice.
- 8-K · 2026-08-26 · 2.01 Completion of Acquisition or Disposition of Assets; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits
- 8-K · 2026-08-18 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits
- 10-Q · 2026-08-14
- 8-K · 2026-08-13 · 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 2.03 Creation of a Direct Financial Obligation; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits
- 8-K · 2026-08-11 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits
- 8-K · 2026-08-05 · 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits
Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price. Reporting, not investment advice. No price targets and no trading recommendations. Figures from the SEC’s own data · every filing · this page as JSON · ask about another company